WKYT: “Lexington cancer doctor saving women’s lives”
Cesium-131 Brachytherapy pioneer, Dr. Jonathan Feddock was recently featured by WKYT, leading the fight against recurrent gynecologic cancer. “It's estimated every six minutes in this country, a doctor diagnoses a woman with gynecologic cancer or cancer of the...
read moreIsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
RICHLAND, Wash., July 7, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced...
read more
IsoRay CEO Thomas LaVoy Talks The Future Of Cesium-131 Brachytherapy With The Wall Street Transcript
The Wall Street Transcipt recently sat with IsoRay CEO Thomas LaVoy to gain insights into the company's isotope used in brachytherapy, the patient experience, and the future of Cesium-131 in additional markets. IsoRay, Inc. (NYSEMKT: ISR) THOMAS LAVOY is Chairman of...
read more
New guidelines and targeted treatment: insights from AUA 2017
Amidst a trove of news surrounding prostate cancer treatment, the 2017 edition of the American Urological Association annual conference convened earlier this month in Boston. The meeting hosted approximately 10,000 attendees and maintained its focus on prostate cancer...
read more
Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
read moreIntermediate Risk Prostate Cancer May Be Safely Controlled with Brachytherapy Alone
In recent phase 3 clinical research, findings suggest that prostate cancer patients treated with brachytherapy alone receive similar outcomes to patients who received brachytherapy with additional external radiation. These findings are among recent data that show the...
read moreIsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”
At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...
read moreMichigan Medicine opens first clinic in the United States that focuses on prostate cancer risk
In recent news, the University of Michigan has opened the first prostate cancer risk clinic in the nation. The clinic aims to monitor and identify the risk of prostate in cancer in men with genetic predisposition to the disease through increased screening methods and...
read more
ABS 2017 Insights and Takeaways
A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray’s ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.
read moreIsoray Patients Tell Their Stories
Herbert L During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...
read more